Literature DB >> 19178792

The efficacy of topical antibiofilm agents in a sheep model of rhinosinusitis.

Tong Le1, Alkis Psaltis, Lor Wai Tan, Peter-John Wormald.   

Abstract

BACKGROUND: Biofilms have been shown to be resistant to conventional antibiotic treatment. This study uses a sheep biofilm model developed by our department to investigate several novel topical anti-biofilm treatments.
METHODS: Staphylococcal biofilms were grown in 54 sheep frontal sinuses over 8 days: Each sinus was randomized to (1) no intervention, (2) single mupirocin flush, (3) regular 12-hourly mupirocin flushes for 5 days, (4) Citric Acid Zwitterionic Surfactant (CAZS) via hydrodebrider, (5) gallium nitrate, (6) CAZS with gallium nitrate, (7) CAZS with mupirocin, and (8) saline regular flushes. Sheep were sacrificed and the sinus mucosa harvested 1 or 8 days after treatment to assess treatment and any biofilm regrowth. Confocal scanning laser microscopy was used to confirm the presence or absence of biofilms, and the extent of biofilm reduction was quantitated using fluorescent in situ hybridization and colony forming unit counts.
RESULTS: In the control sheep biofilm coverage averaged 31.7%. Saline and mupirocin b.d. washes for 5 days had 23% and 0.84% coverage, respectively, when harvested on day 8. A single mupirocin and gallium wash had 7.7% and 16.2% on day 1 and 5.88% and 16.0% on day 8. CAZS with hydrodebrider had 6.66% on day 1 but 21.95% on day 8 whereas CAZS with hydodebrider and gallium had 13.3% on day 8.
CONCLUSION: This study shows that regular treatment with mupirocin produced the most marked reduction in biofilm surface area coverage (0.84% and 1.25%) with sustained effects over the 8-day follow-up period.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19178792     DOI: 10.2500/ajr.2008.22.3232

Source DB:  PubMed          Journal:  Am J Rhinol        ISSN: 1050-6586


  14 in total

1.  The impact of intraoperative saline irrigations on bacterial load within the maxillary sinus.

Authors:  Kristin A Seiberling; Richard K McHugh; Wilson Aruni; Christopher A Church
Journal:  Int Forum Allergy Rhinol       Date:  2011-06-14       Impact factor: 3.858

Review 2.  Advances in the surgical management of chronic sinusitis and nasal polyps.

Authors:  Vijay R Ramakrishnan; David W Kennedy
Journal:  Curr Allergy Asthma Rep       Date:  2011-06       Impact factor: 4.806

Review 3.  Role of bacterial and fungal biofilms in chronic rhinosinusitis.

Authors:  Andrew Foreman; Sam Boase; Alkis Psaltis; Peter-John Wormald
Journal:  Curr Allergy Asthma Rep       Date:  2012-04       Impact factor: 4.806

4.  Topical Drug Delivery for Chronic Rhinosinusitis.

Authors:  Jonathan Liang; Andrew P Lane
Journal:  Curr Otorhinolaryngol Rep       Date:  2012-12-27

Review 5.  Surfactants in the management of rhinopathologies.

Authors:  Philip L Rosen; James N Palmer; Bert W O'Malley; Noam A Cohen
Journal:  Am J Rhinol Allergy       Date:  2013 May-Jun       Impact factor: 2.467

6.  Biofilms in pediatric respiratory and related infections.

Authors:  Yi-Chun Carol Liu; J Christopher Post
Journal:  Curr Allergy Asthma Rep       Date:  2009-11       Impact factor: 4.806

7.  The effect of intraoperative mupirocin irrigation on Staphylococcus aureus within the maxillary sinus.

Authors:  Kristin A Seiberling; Wilson Aruni; Shawn Kim; Victor I Scapa; Hansel Fletcher; Christopher A Church
Journal:  Int Forum Allergy Rhinol       Date:  2012-11-28       Impact factor: 3.858

8.  The role of topical therapies in the treatment of chronic rhinosinusitis.

Authors:  Jeffrey D Suh; Vijay Ramakrishnan; Alexander G Chiu
Journal:  Braz J Otorhinolaryngol       Date:  2011 Nov-Dec

Review 9.  From in vitro to in vivo Models of Bacterial Biofilm-Related Infections.

Authors:  David Lebeaux; Ashwini Chauhan; Olaya Rendueles; Christophe Beloin
Journal:  Pathogens       Date:  2013-05-13

10.  Update on the management of chronic rhinosinusitis.

Authors:  Rachel B Cain; Devyani Lal
Journal:  Infect Drug Resist       Date:  2013-01-23       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.